@article{oai:repo.qst.go.jp:00056055,
 author = {栗原, 千絵子 and 飯塚 均 and 井上, 登美夫 and 栗原 千絵子},
 issue = {4},
 journal = {臨床評価},
 month = {Apr},
 note = {practicality of quantitative imaging biomarkers, established by the Radiological Society of North
America (RSNA) in 2007. They are engaged in development of procedures of assessment and validation of
imaging biomarkers of various imaging modalities such as PET (positron emission tomography); MRI
(magnetic resonance imaging); CT (computed tomography), and US (ultra sound), etc., to be utilized in
both clinical practice and therapeutic drug development. Main participants are radiologists and medical
physicists, collaborating with stake holders such as industries of diagnostic devices, software, therapeutic
drugs, as well as regulatory authorities, such as United States Food and Drug Administration (FDA) and
governmental institutes such as National Institute of Standards and Technology (NIST). They have formed
several working groups of each modality to develop “QIBA profiles” which describe “claims” and
“requirements” needed for assessment, validation, and standardization for the utility of each imaging
biomarker, which would be incorporated into specifications of imaging tools, as medical products.
　　In 2016, Japan Radiological Society (JRS) set up a working group to take part in QIBA’s initiative and
has been facilitating collaboration with international participants in this activity with prospects for the
future possibility of global standardization of imaging biomarkers to be utilized in clinical practice, as well
as drug development.},
 pages = {785--91},
 title = {分子イメージングバイオマーカーの 世界標準化に向けて： QIBAの取り組みと医薬品開発への応用},
 volume = {44},
 year = {2017}
}